A Preventative Adenoviral-Based H5N1 Influenza Vaccine

基于腺病毒的预防性 H5N1 流感疫苗

基本信息

  • 批准号:
    7266987
  • 负责人:
  • 金额:
    $ 24.36万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-08-01 至 2010-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Wild waterfowl, the natural hosts of all known influenza A viruses, are the source of viruses which cause sporadic outbreaks of highly fatal disease in domestic poultry. Since 1997, highly pathogenic (HP) avian influenza A H5N1 viruses have caused a series of outbreaks in Hong Kong, and most recently in 9 other Asian countries. As human exposure to and infection with H5N1 viruses continues to increase, so too does the likelihood of the generation of an avian-human reassortant virus which may transmit efficiently within the human population which lacks HA-specific immunity to H5N1 viruses. In 1997, HPAl H5N1 in Hong Kong resulted in transmission from poultry to humans, resulting in 18 infected people and six deaths. In 2003- 2005, extensive outbreaks of highly pathogenic avian influenza A (H5N1) occurred in several Asian countries (Cambodia, China, Indonesia, Japan, Laos, South Korea, Thailand and Vietnam, North Korea), resulting in 17 human cases in Thailand and 27 in Vietnam and 3 in Cambodia; there were 51 reported deaths. H5N1 infections in family clusters have raised the possibility of human-to-human transmission of H5N1 virus. We have recently developed an adenoviral-based influenza vaccine encoding the hemagglutinin (HA) antigen of the A/Vietnam/1203/2004 (H5N1) strain isolated during the 2003-2005 lethal human outbreak. Vaccinated mice and chickens had broad virus-specific cellular and humoral immunity and were fully protected from a lethal intranasal H5N1 challenge, whereas all control animals died within few days. Hence, a centralized and integrated clinical vaccine testing will be proposed.
性状(由申请方提供):野生水禽是所有已知甲型流感病毒的天然宿主,是导致家禽中高致死性疾病零星暴发的病毒来源。自1997年以来,高致病性(HP)甲型禽流感H5 N1病毒在香港引起了一系列疫情,最近在其他9个亚洲国家爆发。随着人类暴露于H5 N1病毒和感染H5 N1病毒的持续增加,产生禽-人重组病毒的可能性也在增加,该病毒可在缺乏对H5 N1病毒的HA特异性免疫力的人群中有效传播。1997年,HPA 1 H5 N1在香港导致从家禽传播给人类,导致18人感染和6人死亡。在2003- 2005年期间,高致病性禽流感A(H5 N1)在几个亚洲国家(柬埔寨、中国、印度尼西亚、日本、老挝、韩国、泰国和越南、朝鲜)大规模爆发,导致泰国17例人间病例,越南27例,柬埔寨3例;有51例报告死亡。家庭聚集性H5 N1感染增加了H5 N1病毒人际传播的可能性。我们最近开发了一种基于腺病毒的流感疫苗,该疫苗编码在2003-2005年致命的人类疫情期间分离的A/Vietnam/1203/2004(H5 N1)毒株的血凝素(HA)抗原。接种疫苗的小鼠和鸡具有广泛的病毒特异性细胞和体液免疫,并完全免受致命的鼻内H5 N1攻击,而所有对照动物在几天内死亡。因此,将提出集中和综合的疫苗临床试验。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Assessment of route of administration and dose escalation for an adenovirus-based influenza A Virus (H5N1) vaccine in chickens.
评估基于腺病毒的甲型流感病毒 (H5N1) 鸡疫苗的给药途径和剂量递增。
  • DOI:
    10.1128/cvi.00180-10
  • 发表时间:
    2010
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Steitz,Julia;Wagner,RobertA;Bristol,Tyler;Gao,Wentao;Donis,RubenO;Gambotto,Andrea
  • 通讯作者:
    Gambotto,Andrea
A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice.
  • DOI:
    10.1371/journal.pone.0010492
  • 发表时间:
    2010-05-05
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Steitz J;Barlow PG;Hossain J;Kim E;Okada K;Kenniston T;Rea S;Donis RO;Gambotto A
  • 通讯作者:
    Gambotto A
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREA GAMBOTTO其他文献

ANDREA GAMBOTTO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREA GAMBOTTO', 18)}}的其他基金

U01 Proposal Transfer - 2021
U01 提案转让 - 2021
  • 批准号:
    10406767
  • 财政年份:
    2019
  • 资助金额:
    $ 24.36万
  • 项目类别:
Pre-clinical evaluation of a Zika virus vaccine
寨卡病毒疫苗的临床前评估
  • 批准号:
    9294463
  • 财政年份:
    2017
  • 资助金额:
    $ 24.36万
  • 项目类别:
Pre-clinical evaluation of an adenoviral-based MERS-CoV vaccine
基于腺病毒的 MERS-CoV 疫苗的临床前评估
  • 批准号:
    8839373
  • 财政年份:
    2015
  • 资助金额:
    $ 24.36万
  • 项目类别:
Pre-clinical evaluation of an adenoviral-based MERS-CoV vaccine
基于腺病毒的 MERS-CoV 疫苗的临床前评估
  • 批准号:
    9108846
  • 财政年份:
    2015
  • 资助金额:
    $ 24.36万
  • 项目类别:
Adenoviral-based vaccine platform to overcome neutralizing immunity
基于腺病毒的疫苗平台克服中和免疫
  • 批准号:
    7777925
  • 财政年份:
    2010
  • 资助金额:
    $ 24.36万
  • 项目类别:
Adenoviral-based vaccine platform to overcome neutralizing immunity
基于腺病毒的疫苗平台克服中和免疫
  • 批准号:
    8070415
  • 财政年份:
    2010
  • 资助金额:
    $ 24.36万
  • 项目类别:
VECTOR CORE FACILITY
矢量核心设施
  • 批准号:
    8181037
  • 财政年份:
    2010
  • 资助金额:
    $ 24.36万
  • 项目类别:
A Preventative Adenoviral-Based H5N1 Influenza Vaccine
基于腺病毒的预防性 H5N1 流感疫苗
  • 批准号:
    7077267
  • 财政年份:
    2006
  • 资助金额:
    $ 24.36万
  • 项目类别:
VECTOR CORE
矢量核心
  • 批准号:
    7127020
  • 财政年份:
    2005
  • 资助金额:
    $ 24.36万
  • 项目类别:
Preclinical Vector Core
临床前载体核心
  • 批准号:
    7144460
  • 财政年份:
    2005
  • 资助金额:
    $ 24.36万
  • 项目类别:

相似海外基金

cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma
cGAS-STING 通路靶向具有 CD46 趋向性和 AFP 启动子的复制腺病毒条件性复制限制用于治疗肝细胞癌
  • 批准号:
    10436626
  • 财政年份:
    2021
  • 资助金额:
    $ 24.36万
  • 项目类别:
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10557162
  • 财政年份:
    2021
  • 资助金额:
    $ 24.36万
  • 项目类别:
Molecular therapy of replication-competent adenoviruses targeting characteristic gene mutations found in mesothelioma
针对间皮瘤中发现的特征基因突变的具有复制能力的腺病毒的分子疗法
  • 批准号:
    21K08199
  • 财政年份:
    2021
  • 资助金额:
    $ 24.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
  • 批准号:
    10330464
  • 财政年份:
    2021
  • 资助金额:
    $ 24.36万
  • 项目类别:
Structural characterization of nucleoprotein cores of human adenoviruses
人腺病毒核蛋白核心的结构表征
  • 批准号:
    9807741
  • 财政年份:
    2019
  • 资助金额:
    $ 24.36万
  • 项目类别:
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2018
  • 资助金额:
    $ 24.36万
  • 项目类别:
    Discovery Grants Program - Individual
The therapeutic strategies with augmented replications of oncolytic adenoviruses for malignant mesothelioma
溶瘤腺病毒增强复制治疗恶性间皮瘤的治疗策略
  • 批准号:
    18K15937
  • 财政年份:
    2018
  • 资助金额:
    $ 24.36万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular biology and pathogenesis of fowl adenoviruses
禽腺病毒的分子生物学和发病机制
  • 批准号:
    41625-2013
  • 财政年份:
    2017
  • 资助金额:
    $ 24.36万
  • 项目类别:
    Discovery Grants Program - Individual
Exploring the effects of nutrient deprivation on T cells and oncolytic adenoviruses, in order to create immune activators for tumour therapy
探索营养剥夺对 T 细胞和溶瘤腺病毒的影响,以创造用于肿瘤治疗的免疫激活剂
  • 批准号:
    1813152
  • 财政年份:
    2016
  • 资助金额:
    $ 24.36万
  • 项目类别:
    Studentship
Research on detection of novel adenoviruses by genetic methods
新型腺病毒的基因检测研究
  • 批准号:
    16K09118
  • 财政年份:
    2016
  • 资助金额:
    $ 24.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了